Gene

Olaparib

Biology

Surgery

Mutation

Biochemistry

Poly ADP ribose polymerase

Randomization

Placebo

Alternative medicine

Genetics

BRCA mutation

Bevacizumab

Polymerase

Internal medicine

Clinical endpoint

Chemotherapy

Confidence interval

Hazard ratio

Maintenance therapy

Oncology

Medicine

Chemistry

Ovarian cancer

Cancer

Randomized controlled trial

Pathology

New England Journal of Medicine

Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of combining maintenance olaparib and bevacizumab in patients regardless of BRCA mutation status is unknown.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer